At the time of writing, Immunocore Holdings plc ADR [IMCR] stock is trading at $30.43, up 5.99%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The IMCR shares have gain 7.64% over the last week, with a monthly amount glided 2.22%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Immunocore Holdings plc ADR [NASDAQ: IMCR] stock has seen the most recent analyst activity on December 13, 2024, when Morgan Stanley downgraded its rating to a Equal-Weight and also revised its price target to $35 from $74. Previously, Mizuho downgraded its rating to Neutral on November 11, 2024, and dropped its price target to $38. On October 24, 2024, UBS initiated with a Sell rating and assigned a price target of $24 on the stock. Guggenheim downgraded its rating to a Neutral. Leerink Partners initiated its recommendation with a Outperform and recommended $74 as its price target on April 29, 2024. In a note dated November 02, 2023, Cantor Fitzgerald initiated an Overweight rating.
For the past year, the stock price of Immunocore Holdings plc ADR fluctuated between $27.19 and $66.00. Currently, Wall Street analysts expect the stock to reach $29.5 within the next 12 months. Immunocore Holdings plc ADR [NASDAQ: IMCR] shares were valued at $30.43 at the most recent close of the market. An investor can expect a potential drop of -3.06% based on the average IMCR price forecast.
Analyzing the IMCR fundamentals
According to Immunocore Holdings plc ADR [NASDAQ:IMCR], the company’s sales were 310.29M for trailing twelve months, which represents an 17.66% jump. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -0.23%, Pretax Profit Margin comes in at -0.17%, and Net Profit Margin reading is -0.16%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is -0.14 and Total Capital is -0.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 29.21 points at the first support level, and at 28.00 for the second support level. However, for the 1st resistance point, the stock is sitting at 31.64, and for the 2nd resistance point, it is at 32.86.
Ratios To Look Out For
It is important to note that Immunocore Holdings plc ADR [NASDAQ:IMCR] has a current ratio of 4.38. Also, the Quick Ratio is 4.36, while the Cash Ratio stands at 2.15. Considering the valuation of this stock, the price to sales ratio is 4.91, the price to book ratio is 4.25.
Transactions by insiders
Recent insider trading involved BAKER BROS. ADVISORS LP, Director, that happened on Mar 17 ’25 when 0.81 million shares were purchased. affiliate, Brian Di Donato completed a deal on Mar 17 ’25 to buy 100000.0 shares. Meanwhile, affiliate Brian Di Donato bought 56250.0 shares on Mar 14 ’25.
